Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article is for informational purposes only. It is not medical advice, diagnosis, or treatment. Not medical advice. Vitamin D affects calcium metabolism and interacts with several medication classes. Consult a qualified healthcare professional before starting or adjusting supplementation, particularly if you have kidney disease, granulomatous conditions, or take thiazide diuretics or blood thinners.

The question worth starting with

If Japan receives meaningful sunshine across most of its latitude range, and older Japanese adults do spend time outdoors, why does severe vitamin D deficiency appear so consistently in clinical data on Japanese aging populations?

Part of the answer is cultural — Japan’s sun-avoidance norms are well documented. But the more fundamental issue is structural: the sun Japan receives and the UVB that drives vitamin D synthesis are not the same thing. That gap, and what to do about it, is what this article covers.

How cutaneous vitamin D synthesis actually works

Skin synthesis is photochemical, not thermal. Warmth and visible brightness do not drive vitamin D production. What does: UVB radiation in the 290–315 nm wavelength range. When that specific band reaches skin, it converts 7-dehydrocholesterol (7-DHC) in the epidermis to pre-vitamin D3, which undergoes thermal conversion to cholecalciferol (vitamin D3) over the following 24–48 hours.

Several variables reduce synthesis efficiency, independent of how sunny it appears outside:

Solar elevation angle and atmospheric filtering. At low sun angles — early morning, late afternoon, and all winter days at mid-to-high latitudes — the UVB band travels a longer atmospheric path before reaching the surface. A practical measure is the UV Index: meaningful cutaneous vitamin D synthesis is associated with UV Index values of 3 or higher. Below that, the 290–315 nm fraction reaching the skin surface is insufficient for material production regardless of how bright the day looks.

Age-related reduction in 7-DHC. Skin 7-DHC content decreases substantially with aging. According to controlled laboratory measurements comparing age groups under equivalent UV exposure conditions, adults in their seventies synthesize vitamin D3 at roughly 25–30% the rate of young adults. The pathway exists but operates at meaningfully lower efficiency.

Coverage and UV-blocking products. Correctly applied SPF 30 sunscreen blocks approximately 97% of incident UVB — reducing what reaches the skin to roughly 3% of the ambient radiation. Clothing coverage has a comparable effect for the areas it covers. Both are relevant in Japan, where UV-protective behavior is culturally normative across age groups and especially consistent among older women.

Japan’s UVB calendar across its latitude range

Japan spans roughly 26°N (Okinawa main island) to 45°N (central Hokkaido) — a range that translates into meaningfully different solar exposure profiles by season.

Peak summer (May–September). At Tokyo’s latitude (~35°N), midday UV Index regularly reaches 8–11 during June and July. This is genuine opportunity for synthesis. Brief midday exposure during these months — with the specific duration varying substantially by skin tone, body surface area exposed, and cloud cover — can contribute meaningfully to 25(OH)D levels. At Okinawa’s lower latitude, the high-UV window extends further into shoulder months on both ends of summer.

October through March: the structural gap. At latitudes of 35°N and above, winter solar angles drive the UVB fraction to near-zero at ground level. Hokkaido loses meaningful outdoor vitamin D synthesis potential from roughly October through April. Tokyo’s synthesis window contracts significantly from November through February. A cloudless January day in Tokyo can feel bright and cold, but the UV Index reading at noon — often below 2 — tells the more accurate story for synthesis purposes. No practical amount of outdoor time on those days drives meaningful cutaneous production.

Urban lifestyle compound. Japan’s National Health and Nutrition Survey data documents average daily outdoor time among adults 65 and older in urban settings that falls well short of what would be needed to accumulate meaningful summer synthesis across the week — even during the months when solar angles technically support it. The combination of cultural sun avoidance in summer and architectural/behavioral indoor time in winter creates a year-round deficit pattern in a large share of the older urban population.

The result: Japan’s summer UVB at mid-latitudes is adequate in principle. The behavioral and seasonal factors ensure that a substantial fraction of older adults do not access it consistently enough to maintain vitamin D status without dietary or supplemental contribution.

Immune function and what the trial record actually shows

The immune connection to vitamin D status has a well-characterized biological basis. Vitamin D receptors (VDR) are expressed on most immune cell types — T helper cells, T regulatory cells, B cells, monocytes, and macrophages. Active vitamin D metabolite (1,25-dihydroxyvitamin D) modulates both innate immune pattern-recognition responses and the adaptive immune inflammatory cascade. This receptor expression is real and well-replicated; the clinical implications in healthy humans are more specific than popular coverage suggests.

The most directly applicable trial evidence addresses acute respiratory infection. A 2017 individual participant data meta-analysis in the British Medical Journal (Martineau et al.) pooled data from 25 randomized controlled trials covering over 11,000 participants. The analysis found that vitamin D supplementation was associated with a statistically significant reduction in acute respiratory tract infection incidence. The finding was not uniform across participants: the benefit was most pronounced in those with baseline 25(OH)D below 25 nmol/L — severe deficiency by clinical standards. In that subgroup, the estimated reduction in infection incidence was substantially larger than in participants with adequate baseline levels, where the association was smaller and less consistent.

This pattern — benefit concentrating in the most severely deficient subgroup — has appeared repeatedly in vitamin D trial literature. The practical implication is calibration rather than dismissal. The question is not “does vitamin D supplementation help the immune system” as a universal yes-or-no, but “in whom does correcting deficiency appear to matter.” The Martineau findings point toward the severely deficient as the population where the infection association signal is clearest.

For Japanese older adults in whom 25(OH)D surveys document winter levels regularly dipping below 25 nmol/L — particularly in northern prefectures and urban populations with limited outdoor exposure — the overlap between the deficiency depth documented in cohort data and the deficiency threshold where Martineau et al. found the most consistent association is worth noting. That parallel is not proof that supplementation reduces infections in that specific population; the trial has not been run that way. It does establish why the immune function dimension adds weight to the deficiency question beyond the better-known bone-density narrative.

The complementary data on immune senescence is worth adding. Natural killer (NK) cell activity declines measurably with age as part of immune aging, and maintaining NK function is associated with certain favorable health trajectories in observational data. Vitamin D receptors on NK cells are functionally active, and some smaller trials have found VDR-mediated modulation of NK activity with supplementation. The chain from vitamin D status → NK cell function → immune resilience in aging is biologically plausible and under active investigation. The controlled evidence at the hard outcome level (fewer infections, reduced immune-related morbidity over years) is not yet established, and the Martineau findings are the strongest direct RCT signal available.

When supplementation covers what sun cannot

The October–March gap at most Japanese latitudes creates a structural situation where food and supplemental vitamin D need to compensate for absent cutaneous synthesis. Japan’s traditional diet does contribute via fatty fish consumption, but not at levels that consistently maintain 25(OH)D above 50 nmol/L in older urban adults with limited outdoor exposure — as documented repeatedly in NCGG and JPHC-affiliated survey data.

Vitamin D3 (cholecalciferol) is the preferred supplemental form. It raises serum 25(OH)D more reliably than D2 (ergocalciferol) at equivalent doses — a consistent finding across comparative bioavailability studies, and the reason D3 is the form used in most recent clinical trials. Both D3 and K2 are fat-soluble; absorption is meaningfully better when taken with a meal containing some dietary fat. Softgel and oil-based capsule formats outperform dry-powder tablets in most bioavailability comparisons for this reason.

Doses in the 1,000–2,000 IU/day range are used in published trials, including VITAL (Manson et al., New England Journal of Medicine, 2019), which randomized 25,871 US adults to 2,000 IU/day D3 versus placebo over a median of 5 years. VITAL found no significant reduction in overall all-cause mortality in the primary analysis; post-hoc subgroup analyses suggested differential patterns in participants with lower baseline 25(OH)D, which are hypothesis-generating rather than confirmatory. The dose produced no safety concerns in the general population over 5 years. Correcting severe documented deficiency may require higher doses, which warrant clinician-guided titration and follow-up serum testing.

What to look for when buying

A few format and labeling factors translate directly from the evidence to product selection:

Oil-based softgels. Both D3 and K2 are fat-soluble. Softgel and oil-based capsule formats deliver D3 in a lipid carrier, supporting absorption without requiring specific meal timing beyond a general “take with food” approach. Dry tablet forms show more variable absorption in comparative studies.

MK-7 versus MK-4. The D3+K2 combination — where menaquinone-7 (MK-7, the long-circulating K2 form concentrated in natto) is added to D3 — is offered by several established brands. MK-7 has a longer circulating half-life than MK-4; comparable serum effects with MK-4 require substantially higher doses. Products listing K2 as MK-7 are the closer match to the K2 form studied in dietary observational data.

For D3+K2 products from manufacturers with third-party testing documentation:

• Thorne Vitamin D/K2 — D3 with MK-7 in oil-based capsule; Thorne publishes certificate-of-analysis documentation and is consistently referenced in pharmacist and clinician communities.
• Life Extension Vitamin D3 with K2 — sources MK-7 from natto; Life Extension publishes third-party test results and has a research-forward editorial approach.
• NOW Foods D3+K2 — similar formulation at a lower price point; manufacturer has longstanding ingredient transparency practices.

For D3 alone:

• Nordic Naturals Vitamin D3 — oil-based softgel format with transparent sourcing.
• Thorne Vitamin D3 — consistent manufacturing credentials; available in 1,000 IU and 2,000 IU softgels.

International buyers outside the US can access the brands above through iHerb, which ships to Japan, the UK, Australia, and much of Europe.

Who needs a clinical conversation before starting

Vitamin D at 1,000–2,000 IU/day is well-tolerated across the published trial literature in generally healthy adults, but specific medical situations require clinical evaluation first:

Sarcoidosis, hyperparathyroidism, or granulomatous disease. These conditions involve dysregulated vitamin D metabolism and can produce hypercalcemia at doses that are safe in the general population. Supplementation without clinical supervision in these cases carries real risk.

Chronic kidney disease (stage 3 or higher). The kidney converts vitamin D to its clinically active 1,25-dihydroxyvitamin D form. In significantly reduced kidney function, standard supplementation doses require monitoring.

Thiazide diuretics. This medication class reduces urinary calcium excretion. Combined with supplemental vitamin D, the interaction can raise serum calcium to clinically relevant levels — disclose to a clinician before starting.

Anticoagulants. Some evidence suggests possible interaction at higher supplemental doses. Mention it to a prescribing clinician.

A serum 25(OH)D test through a primary care provider identifies both whether the winter-deficiency pattern the Japanese cohort data describes applies individually, and — if it does — what dose range is clinically appropriate. Given that the immune function association signal in Martineau et al. was concentrated in the severely deficient range, that test is the most rational starting point before selecting a product or dose.

---

For the broader picture of why vitamin D deficiency persists in Japan’s aging population despite dietary fish consumption, see Japan’s Vitamin D Paradox. For the natto-K2 bone evidence in more depth, see Japanese Natto and Vitamin K2.